Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartwatch decode Parkinson's symptoms?

NCT ID NCT05904288

Knowledge-focused Sponsor: Newel Health SRL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers are testing whether data from a commercial smartwatch and a mobile app can help personalize treatment for Parkinson's disease. The study enrolls 54 adults with Parkinson's who take levodopa and experience daily motor fluctuations. Participants wear a Garmin Vivosmart 5 smartwatch and use a mobile app to record symptoms for six months. The goal is to develop machine learning algorithms that predict motor symptom scores from sensor data, which could one day help doctors adjust medication plans remotely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
smartwatch and mobile app for monitoring Parkinson's symptoms
What this could lead to
If the algorithms work, doctors could use everyday smartwatch data to adjust Parkinson's medication more precisely and remotely.
What could go wrong
This is a small, early observational study. The algorithms may not predict symptoms accurately enough for clinical use, and results might not apply to all Parkinson's patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

54 people

The number who actually took part.

Started

Oct 2023

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study targets individuals diagnosed with idiopathic PD which experience wearing-off phenomena.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent (IC) obtained. 2. Age \> 18 years. 3. Male or female patients Meeting the MDS clinical diagnostic criteria for Parkinson's Disease (Postuma et al., 2015) 4. At least one motor symptoms OFF-period each day, excluding early morning akinesia. 5. On treatment with Levodopa 6. Stable Levodopa regimen for 4 weeks before Screening Visit; 7. Levodopa Equivalent Daily Dose (LEDD) \> 400 mg, AND/OR Levodopa Intake \> 2 administration/day; 8. The subject is willing and able to attend study procedures and to use wearable and mobile devices. Exclusion Criteria: 1. Secondary or atypical PD. 2. Cognitive problems which significantly impair his/her ability to give an IC and perform the study tasks. 3. Levodopa Equivalent Daily Dose (LEDD) \> 800 mg, AND/OR Levodopa intake \> 8 administration/day; 4. Any condition that in the opinion of the investigator would interfere with the interpretation of the study results or constitute a health risk for the subject if he/she takes part in the study. 5. Concomitant participation to clinical trials with investigational medicinal products. 6. Failure to show, in opinion of the investigator, acceptable/appropriate use of wearable and mobile device (e.g. weekly average daily wearable wear time \< 8 hours). Having an advanced treatment (including Deep Brain Stimulation, Apomorphine, Duodopa), is not an exclusion criterion, as well as the subject decision or capability to attend the exercise and speech training programs within the mobile app.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

Contacts and locations

Locations

  • Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona

    Salerno, Salerno, 84100, Italy

  • IRCCS Fondazione Santa Lucia

    Roma, 00179, Italy

  • IRCCS San Raffaele

    Roma, 00163, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.